Home
Products
Rhamnazin
| Product Name | Rhamnazin |
| Price: | Inquiry |
| Catalog No.: | CN04329 |
| CAS No.: | 552-54-5 |
| Molecular Formula: | C17H14O7 |
| Molecular Weight: | 330.3 g/mol |
| Purity: | >=98% |
| Type of Compound: | Flavonoids |
| Physical Desc.: | Powder |
| Source: | The branches of Rhamnus cathartica |
| Solvent: | Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc. |
| SMILES: |
| Contact us | |
|---|---|
| First Name: | |
| Last Name: | |
| E-mail: | |
| Question: | |
| Description | Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy[1]. Rhamnazin shows antioxidant and anti-inflammatory properties[2]. |
| Target | VEGFR2:4.68 μM (IC50) |
| In Vitro | Rhamnazin (5-40 μM) 抑制 VEGF 诱导的 HUVECs 增殖、迁移和成管[1]。 Rhamnazin (0-20 μM) 降低 VEGFR-2 酪氨酸激酶活性和 VEGFR-2 信号通路[1]。 Rhamnazin (0-40 μM; 24 h) 抑制乳腺癌细胞增殖和 VEGFR2 信号通路[1]。 Cell Migration Assay [1] Cell Line: HUVECs Concentration: 0, 10, 15 and 20 μM Incubation Time: 6 h Result: Strongly inhibited the migration of HUVECs. Western Blot Analysis[1] Cell Line: HUVECs Concentration: 0, 10, 15 and 20 μM Incubation Time: 24 h Result: Decreased VEGF binding to VEGFR2. Reduced VEGF-stimulated phosphorylation of VEGFR2 and its downstream MAPK, AKT, and STAT3 in HUVECs in a concentrationdependent manner. Cell Proliferation Assay[1] Cell Line: HCC1937, T-47D, SK-BR-3, MCF-7 and MDA-MB-231 Concentration: 0, 10, 15, 20, 30 and 40 μM Incubation Time: 24 h Result: Inhibited cell growth with IC50s of 19, 27, 32, 41 and 64 μM against MDA-MB-231, MCF-7, SK-BR-3, T-47D and HCC1937 in the presence of VEGF, respectively. |
| In Vivo | Rhamnazin (200 mg/kg; i.g.; daily for 25 days) 抑制小鼠乳腺癌生长和血管生成[1]。 Rhamnazin (5-20 mg/kg; i.p.; once) 在大鼠急性肺损伤模型中显示出较强的抗氧化和抗炎作用[2]。 Animal Model: BALB/c nude mice, breast cancer xenograft model[1] Dosage: 200 mg/kg Administration: Intragastric administration, daily for 25 days Result: Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3. |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 591.6±50.0 °C at 760 mmHg |
| Flash Point | 221.2±23.6 °C |
| Exact Mass | 330.073944 |
| PSA | 109.36000 |
| LogP | 2.26 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |